Australia markets closed

Xeris Biopharma Holdings, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9200+0.1000 (+5.49%)
At close: 4:00PM EDT
2.0000 +0.08 (+4.17%)
Pre-market: 04:16AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.8200
Bid0.0000 x 3100
Ask0.0000 x 2900
Day's range1.9000 - 2.1500
52-week range1.7700 - 7.9400
Avg. volume3,408,637
Market cap240.632M
Beta (5Y monthly)1.81
PE ratio (TTM)N/A
EPS (TTM)-1.4730
Earnings date08 Nov 2021 - 12 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
  • Business Wire

    Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

    CHICAGO, October 25, 2021--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris’ suspension-based formulation technology, XeriJect™, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulation

  • Business Wire

    Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

    CHICAGO, October 05, 2021--Xeris Pharmaceuticals, Inc. ("Xeris"), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) ("Strongbridge"). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin

  • GlobeNewswire

    Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

    DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The Court sanction hearing in relation to